Renaissance Technologies LLC Decreases Stock Holdings in BioAtla, Inc. (NASDAQ:BCAB)

Renaissance Technologies LLC trimmed its holdings in shares of BioAtla, Inc. (NASDAQ:BCAB) by 37.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 625,500 shares of the company’s stock after selling 370,800 shares during the quarter. Renaissance Technologies LLC owned 1.30% of BioAtla worth $857,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of BCAB. Perceptive Advisors LLC purchased a new stake in shares of BioAtla during the fourth quarter valued at approximately $180,000. PVG Asset Management Corp purchased a new stake in BioAtla in the fourth quarter worth $161,000. Chase Investment Counsel Corp purchased a new stake in BioAtla in the first quarter worth $263,000. Vanguard Group Inc. increased its position in BioAtla by 0.8% in the first quarter. Vanguard Group Inc. now owns 2,099,037 shares of the company’s stock worth $7,221,000 after buying an additional 17,667 shares during the last quarter. Finally, Acadian Asset Management LLC increased its position in BioAtla by 57.6% in the first quarter. Acadian Asset Management LLC now owns 155,188 shares of the company’s stock worth $532,000 after buying an additional 56,748 shares during the last quarter. 77.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of BioAtla in a research report on Monday, September 16th.

BioAtla Price Performance

NASDAQ:BCAB opened at $2.15 on Tuesday. The business has a fifty day simple moving average of $1.74 and a two-hundred day simple moving average of $2.06. BioAtla, Inc. has a 1 year low of $1.14 and a 1 year high of $4.02. The company has a market capitalization of $103.45 million, a P/E ratio of -0.86 and a beta of 1.06.

BioAtla (NASDAQ:BCAB) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.01. During the same period in the previous year, the firm earned ($0.75) earnings per share. As a group, analysts anticipate that BioAtla, Inc. will post -1.52 earnings per share for the current year.

BioAtla Profile

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.